NCT00697879View on ClinicalTrials.gov

Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2011

Conditions
Solid Tumor
Interventions
DRUG

CHR-3996

Once daily oral ingestion of capsules (5, 10, 20 or 40 mg), dose depending on cohort, treatment cycle of 28 days

Trial Locations (3)

3015 CE

Erasmus MC University Medical Center - Location Centrum, Rotterdam

3075 EA

Erasmus University Medical Center - Location Daniel den Hoed, Rotterdam

SM2 5PT

The Royal Marsden Hospital, Sutton

Sponsors
All Listed Sponsors
lead

Chroma Therapeutics

INDUSTRY

NCT00697879 - Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours | Biotech Hunter | Biotech Hunter